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Abstract
Background: A liver-derived protein, fetuin-A, was first purified from calf fetal serum in 1944, but its potential role in lethal
systemic inflammation was previously unknown. This study aims to delineate the molecular mechanisms underlying the
regulation of hepatic fetuin-A expression during lethal systemic inflammation (LSI), and investigated whether alterations of
fetuin-A levels affect animal survival, and influence systemic accumulation of a late mediator, HMGB1.
Methods and Findings: LSI was induced by endotoxemia or cecal ligation and puncture (CLP) in fetuin-A knock-out or wild-
type mice, and animal survival rates were compared. Murine peritoneal macrophages were challenged with exogenous
(endotoxin) or endogenous (IFN-c) stimuli in the absence or presence of fetuin-A, and HMGB1 expression and release was
assessed. Circulating fetuin-A levels were decreased in a time-dependent manner, starting between 26 h, reaching a nadir
around 24–48 h, and returning towards base-line approximately 72 h post onset of endotoxemia or sepsis. These dynamic
changes were mirrored by an early cytokine IFN-c-mediated inhibition (up to 50–70%) of hepatic fetuin-A expression.
Disruption of fetuin-A expression rendered animals more susceptible to LSI, whereas supplementation of fetuin-A (20–
100 mg/kg) dose-dependently increased animal survival rates. The protection was associated with a significant reduction in
systemic HMGB1 accumulation in vivo, and parallel inhibition of IFN-c- or LPS-induced HMGB1 release in vitro.
Conclusions: These experimental data suggest that fetuin-A is protective against lethal systemic inflammation partly by
inhibiting active HMGB1 release.
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Introduction
Sepsis refers to a systemic inflammatory response syndrome
resulting from a microbial infection, and is partly propagated by
innate immune cells such as macrophages. Macrophages are
equipped with pattern recognition receptors (such as TLR2,
TLR4, and TLR9) [1–3], and can recognize pathogen-associated
molecular patterns (PAMPs, such as endotoxin) [3–6], as well as
damage-associated molecular patterns (DAMPs, such as HMGB1)
[3,4,7,8]. In response to various PAMPs or DAMPs, innate
immune cells release many cytokines (such as TNF-a, IL-1, or
IFN-c) to orchestrate an inflammatory response [9]. Although an
appropriate response is required to defend against infection, an
uncontrolled systemic inflammation may adversely contribute to
the pathogenesis of sepsis.
We discovered that HMGB1 is released by activated macrophages
[5], and contributes to the pathogenesis of sepsis [10]. Like other
danger signal molecules (such as heat shock proteins) [11,12],
extracellular HMGB1 functions as an alarmin signal to recruit, alert,
and activate innate immune cells [10,13]. For instance, HMGB1 can
activate immune cells to produce various cytokines and chemokines
[7,8,14–16], thereby sustaining a potentially injurious inflammatory
response in sepsis [10,13].Consistently, anti-HMGB1 antibodies [5,17]
or inhibitors (e.g., tanshinones, ethyl pyruvate, nicotine, stearoyl
lysophosphatidylcholine, or epigallocatechin-3-gallate) [5,18–24] con-
fer protection in animal models of endotoxemia and sepsis.
The liver orchestrates a host defense response by altering (re-
prioritizing) the synthesis and systemic release of ‘‘acute phase
proteins’’ (APPs, such as fetuin-A, also termed the alpha-2-HS-
glycoprotein for the human homologue) [25]. The expression of
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TNF-a, IL-1, and IL-6 [26], classifying it as a negative APP [27,28].
However, plasma fetuin-A levels were elevated in patients after
ischemic stroke [29,30] or cattle after trauma [31], implying that
fetuin-A may also function as a positive APP. A wide range of
biological functions have been proposed for fetuin-A based on either
its structural similarities to other proteins, or interaction with biogenic
molecules. For instance, fetuin-A shares sequence similarity to insulin
receptor tyrosine kinase [32,33] and type II TGF-b receptor [34],
and has thus been proposed as an inhibitor of insulin or TGF-
bsignaling pathways. As a glycoprotein, fetuin-A carries two N-linked
and three O-linked oligosaccharide chains that terminate with sialic
acid residues, and can bind biogenic cationic ions (e.g., Ca
2+)a n d
other anti-inflammatory molecules (e.g., spermine) [35,36]. Accord-
ingly, fetuin-A has been proposed as an endogenous inhibitor of
pathological mineralization/calcification [37–40], and an opsonin of
cationic molecules (such as spermine) [36].
At extremely high concentrations (e.g., 3500 mg/ml), crude
bovine fetuin-A preparation (purity .98%, Sigma-Aldrich)
abolishes LPS (10 mg/ml)-induced release of nitric oxide and IL-
1b in macrophage cultures [41]. In animal models of carrageenan-
induced paw edema or cerebral ischemia, administration of fetuin-
A merely attenuated early, but not late, inflammatory response in
the paw [42] or ischemic brain [43]. It was previously unknown
whether: i) fetuin-A functions as a negative or positive APP in
lethal systemic inflammation (LSI), ii) other early proinflammatory
cytokines also counter-regulate hepatic fetuin-A expression, iii)
fetuin-A confers a long-lasting protection against LSI by inhibiting
late proinflammatory mediators. Here we showed that fetuin-A
functions as a negative APP, and confers protection against LSI
partly by attenuating HMGB1 release.
Results
Circulating fetuin-A levels were temporally reduced in
lethal endotoxemia and sepsis
To understand the role of fetuin-A in LSI, we measured its
circulating levels in murine models of lethal endotoxemia and
sepsis. Circulating fetuin-A levels were decreased in both
endotoxemic (Fig. 1A) and septic (Fig. 1B) mice in a time-
dependent fashion, with maximal reduction (by 50–60%) 24–48 h
after onset of these diseases. Afterwards, fetuin-A levels started to
increase, returning towards basal levels approximately 72 h post
endotoxemia (Fig. 1A) or sepsis (Fig. 1B), supporting the notion
that fetuin-A functions as a negative APP in murine models of LSI.
Role of early proinflammatory cytokines in the regulation
of hepatic fetuin-A expression
To understand the mechanisms underlying regulation of fetuin-A
expression during LSI, we examined the impact of early cytokines on
hepatic fetuin-A expression. Consistent with a previous report [26], an
early cytokine, TNF-a (50–100 ng/ml), effectively inhibited fetuin-A
expression in HepG2 cells (by .50–60%, data not shown). Moreover,
another early cytokine, IFN-c, at concentrations as low as 10–50 ng/
ml, markedly inhibited hepatic fetuin-A expression (by 50–70%) in a
time-dependent fashion (Fig. 2A, bottom panel). To confirm the
role of IFN-c in the regulation of fetuin-A expression, we investigated
whether disruption of IFN-c expression impairs endotoxin-mediated
down-regulation of fetuin-A expression. The basal hepatic (Fig. 2B,
top panel) and circulating (Fig. 2B, bottom panel) fetuin-A levels
were not significantly different between IFN-c-null and wild-type
Balb/C mice. However, at the dose (10 mg/kg) that significantly
reduced hepatic fetuin-A levels in wild-type mice (Fig. 2B, top
panel), LPS did not significantly reduce neither hepatic (Fig. 2B, top
panel)n o rs e r u m( Fig. 2B, bottom panel) fetuin-A levels in IFN-c-
knockout mice. These experimental data support an important role for
IFN-c in the counter-regulation of fetuin-A expression during an early
stage of endotoxemia.
To understand the potential role for IFN-c in the regulation of
LPS-induced HMGB1 release, we determined whether disruption
of IFN-c expression abrogated LPS-induced systemic HMGB1
accumulation. Consistent with previous report [5], endotoxemia
led to a significant increase in circulating HMGB1 levels in wild-
type Balb/C mice (Fig. 2C). However, this endotoxin-induced
systemic HMGB1 accumulation was almost completely abolished
in IFN-c-deficient mice (Fig. 2C), supporting an important role
for IFN-c in endotoxin-induced HMGB1 release.
Disruption of fetuin-A expression renders animals more
susceptible to endotoxemia and sepsis
To elucidate the role of fetuin-A in systemic inflammatory
diseases, we determined the influence of fetuin-A disruption on
endotoxemic and septic lethality. Sex- and body weight-
matched wild-type or fetuin-A-knockout (KO) C57BL/6J mice
were subjected to endotoxemia or sepsis, and animal survival
Figure 1. Circulating fetuin-A levels were temporally decreased
during endotoxemia and sepsis. Balb/C mice were subjected to
endotoxemia (LPS, 10 mg/kg, i.p.) or sepsis (induced by CLP), and
sacrificed at indicated time points to collect blood. Serum fetuin-A
levels were determined by Western blotting analysis with reference to
standard curve generated with purified fetuin-A at various dilutions,
and expressed as mean 6 SD of 3–6 independent experiments (N=3–
6), with 4–6 animals included in each group. *, P,0.05 versus ‘‘0 h post
LPS’’ (Panel A) or ‘‘0 h post CLP’’ (Panel B).
doi:10.1371/journal.pone.0016945.g001
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(local inflammation), there was no difference in susceptibility
between sex- and body weight-matched (male, 27–30 g) wild-
type and fetuin-A KO mice [43]. However, the animal survival
rates were significantly lower in the fetuin-A KO mice as
compared with wild-type C57BL/6J mice following endotox-
emia (Fig. 3A, top panel)o rs e p s i s( Fig. 3A, bottom
panel). Consistently, disruption of fetuin-A expression led to
significant elevation of serum HMGB1 levels at 48 h post
endotoxemia (8226 ng/ml for Fet
+/+ mice, versus 181645 ng/ml for
Fet
2/2 mice; N=10, P,0.05) or sepsis (125646 ng/ml for Fet
+/+
mice, versus 271634 ng/ml for Fet
2/2mice; N=12, P,0.05). These
experimental data suggest a protective role for a liver-derived negative
APP, fetuin-A, in systemic inflammatory diseases.
Supplementation of fetuin-A conferred protection
against lethal endotoxemia and sepsis
To confirm the role of fetuin-A in LSI, we examined its effects
on animal survival in endotoxemia or sepsis. Repetitive adminis-
tration of fetuin-A (20–100 mg/kg) promoted a dose-dependent
protection against lethal endotoxemia (P,0.05, Fig. 3B, top
panel). In contrast, administration of a control protein,
asialofetuin-A, even at doses up to 100 mg/kg, did not
significantly affect animal survival rates (Fig. 3B, top panel),
suggesting a requirement for the presence of sialic acid in fetuin-A-
mediated protection. In an animal model of sepsis, delayed
administration of fetuin-A (20–100 mg/kg), beginning 24 h after
the onset of sepsis and followed by an additional dose at 48 h post
Figure 2. IFN-c counter-regulates hepatic fetuin-A expression. A). IFN-c decreased fetuin-A expression levels in hepatocytes. HepG2 cells were
stimulated with IFN-c for 16 h at different doses (Top Panel), or at 50 ng/ml for different time periods (Bottom Panel), and cellular fetuin-A/b-actin
ratio was assessed by Western blotting analysis. B, C). Disruption of IFN-c expression rendered mice resistant to LPS-induced down-regulation of hepatic
fetuin-A expression. LPS (10 mg/kg) was administered into wild-type or IFN-c-knockout Balb/C mice, liver and blood was harvested at 24 h (Panel B)
or 52 h (Panel C) post endotoxemia to assess fetuin-A (Panel B) or HMGB1 (Panel C) levels by Western blotting analysis. Hepatic fetuin-A levels, as
a ratio to b-actin, were expressed as mean 6 SD of multiple independent experiments (N=3–5). *, P,0.05 versus control (‘‘-LPS’’).
doi:10.1371/journal.pone.0016945.g002
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animal survival rates from 45% to 90% (P,0.05, Fig. 3B,
bottom panel). Although we did not observe any difference in
the mortality rates between sex- and age-matched Balb/C and
C57BL/6 mice in animal models of sepsis (induced by CLP), we
noticed that wild-type C57BL/6J mice were somewhat less
susceptible to endotoxemia than sex- and age-matched Balb/C
mice (Fig. 3A, 3B, top panels).
Previously, it was shown that at high concentrations (e.g.,
3500 mg/ml), fetuin-A (purity .98%, Sigma-Aldrich) itself
slightly induced nitric oxide release in macrophage cultures
[41], possibly because of chemical impurities contained in the
fetuin-A preparation [41]. Indeed, SDS-PAGE analysis of
‘‘purified’’ fetuin-A preparation (Calbiochem, Cat. No.
#341506) revealed multiple contaminating proteins that co-
purified with the typical fetuin-A ‘‘doublet’’ bands on SDS-
PAGE gels (Fig. 4A). This fetuin-A ‘‘doublet’’ may represent
variable post-translation modifications (such as glycosylation
and/or phosphorylation), and could be separated from other
contaminating proteins by gel filtration (Fig. 4A, left panel),
and from each other by ion-exchange chromatography (Fig. 4A,
right panel). Even at lower doses (10 mg/kg), delayed
administration of this highly purified fetuin-A significantly
increased animal survival rates from 45% to 90% (N=22
mice/group, P,0.05). Taken together, these experimental data
suggest that fetuin-A is protective against lethal systemic
inflammatory diseases.
To gain insight into its protective mechanism, we evaluated
the effects of fetuin-A on systemic accumulation of HMGB1
during a late stage of endotoxemia and sepsis. Administration of
fetuin-A significantly reduced endotoxemia- or sepsis-induced
increase of circulating HMGB1 levels at 52 h post endotoxemia
(Fig. 4B, top panel)o rs e p s i s( Fig. 4B, bottom panel),
suggesting that fetuin-A confers protection by inhibiting
systemic accumulation of late proinflammatory mediator of
these diseases.
Highly purified fetuin-A inhibited active HMGB1 release
in macrophage cultures
To elucidate the mechanisms underlying fetuin-A-mediated
suppression of systemic HMGB1 accumulation in vivo,w e
examined the effects of fetuin-A on IFN-c- and endotoxin-
induced HMGB1release in macrophage cultures.Followingextensive
purification by gel filtration (Fig. 4A, left panel) and ion-exchange
chromatography (Fig. 4A, right panel), the intact fetuin-A was
capable of inhibiting IFN-c-( Fig. 4C) and LPS-induced
Figure 3. Distinct effects of fetuin-A depletion or supplementation on endotoxemic and septic lethality. A). Disruption of fetuin-A
expression rendered mice more susceptible to lethal endotoxemia and sepsis. Sex-, body weight-, and genetic background-matched wild-type or fetuin-
A-deficient (fet
2/2) C57BL/6 mice (male, 27–29 g) were subjected to endotoxemia or sepsis, and animal survival was monitored. The Kaplan-Meier
method was used to compare mortality rates between groups of two independent experiments with similar results. *, p,0.05 vs wild-type mice in
endotoxemia (Top Panel) or sepsis (Bottom Panel). B). Supplementation of fetuin-A protected mice against lethal endotoxemia or sepsis. Balb/C mice
were challenged with lethal dose of endotoxin, and intraperitoneally administered with saline (0.2 ml/mouse), fetuin-A (‘‘Fet’’), or asialofetuin-A (‘‘A-
Fet’’) at +0.5 and +24 h after endotoxemia. In separate experiments, Balb/C mice were subjected to sepsis (induced by CLP), and administered with
fetuin-A at indicated doses at +24, and +48 h after CLP, and animal survival was monitored. *, P,0.05 versus saline.
doi:10.1371/journal.pone.0016945.g003
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tions (e.g., 100 mg/ml) that almost completely abrogated LPS-
induced HMGB1 release, fetuin-A only partly inhibited LPS-
induced TNF-a secretion (Fig. 4D, bottom panel), suggesting
that highly purified fetuin-A is an effective negative regulator of
HMGB1 release.
Fetuin-A did not inhibit endotoxin-induced autophagy,
but reduced cytoplasmic HMGB1 levels
A previous study has implicated a potential role for autophagy
in the regulation of endotoxin-induced HMGB1 release, because
an HMGB1 inhibitor, quercetin, simultaneously inhibits LPS-
Figure 4. Highly purified fetuin-A inhibited HMGB1 release in vivo and in vitro.A ). Purification of fetuin-A by gel filtration and ion-exchange
chromatography. Bovine fetuin-A was obtained from Calbiochem, and further purified by gel filtration and ion-exchange chromatography. Lane ‘‘0’’:
crude fetuin-A from Calbiochem (Cat. #341506), Lane 1–4: consecutive gel filtration fractions. Gel filtration fraction #4 was further purified by ion-
exchange chromatography. Lane 5–6: two major ion-exchange fractions containing a lower (Lane 5) and higher (Lane 6, ‘‘intact’’) molecular weight
protein. B). Administration of fetuin-A decreased circulating HMGB1 levels in endotoxemia and sepsis. Balb/C mice were subjected to lethal endotoxemia
or sepsis, and treated with fetuin-A at +0.5, +24, and +48 h post endotoxemia, or +24 and +48 h post CLP. Blood were collected from normal,
endotoxemic (52 h post LPS), or septic (52 h post CLP) mice, respectively. Serum HMGB1 levels were determined by Western blot analysis, and
expressed as mean 6 SD of two independent experiments in triplicates (N=6). *, P,0.05 versus control ‘‘+LPS’’ or ‘‘+CLP’’ group. C, D). Highly purified
intact fetuin-A inhibited IFN-c- or LPS-induced HMGB1 release in primary peritoneal macrophages. Peritoneal macrophages were isolated form Balb/C
mice, and stimulated with IFN-c or LPS at indicated concentrations in the absence or presence of highly purified intact fetuin-A for 16 h. The culture
medium was assayed for HMGB1 levels by Western blotting analysis (Panel C, D) and TNF-a levels by ELISA (Panel D), and expressed as Mean 6 S.D.
of two independent experiments in triplicates (N=6). *, P,0.05 vs ‘‘+ IFN-c’’ (Panel C)o r‘ ‘ + LPS’’ (Panel D).
doi:10.1371/journal.pone.0016945.g004
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hagosome) and HMGB1 release [44]. To elucidate mechanisms
underlying fetuin-A-mediated suppression of HMGB1 release, we
determined whether fetuin-A affects LPS-induced formation of
LC3-containing cytoplasmic vesicles (autophagosomes). Consistent
with a previous report [45], LPS induced the formation of LC3-
containing cytoplasmic vesicles (autophagosomes) in GFP-LC3-
transfected macrophage cultures (Fig. 5A). In contrast to
quercetin, however, fetuin-A failed to inhibit LPS-induced
formation of LC3-containing punctuate structures in macrophage
cultures (Fig. 5A, top panels). By itself, fetuin-A stimulated the
formation of LC3-containing punctate structures (data not shown),
suggesting a possibility that fetuin-A inhibits HMGB1 release
potentially by stimulating its autophagic degradation.
In addition, we determined whether fetuin-A affects cytoplasmic
HMGB1 levels in endotoxin-stimulated macrophages. Quiescent
macrophages constitutively expressed HMGB1 and maintained an
intracellular ‘‘pool’’ of HMGB1 predominantly in the nucleus
(Fig. 5A, left panels). At 16 h post LPS stimulation, marked
HMGB1 staining was observed in cytoplasmic vesicles (Fig. 5A,
middle panels). However, fetuin-A markedly reduced HMGB1
staining in cytoplasmic regions (Fig. 5A, right panels), suggesting
a possibility that fetuin-AattenuatesHMGB1releasebyreducing its
cytoplasmic levels. To further test this possibility, cytoplasmic and
nuclear fractions were isolated from primary macrophages, and
immunoblotted with antibodies specific for HMGB1, PCNA (a
nuclear protein), or b-actin (a cytoplasmic protein), respectively. In
murine macrophage-like RAW 264.7 cells, LPS merely induced
cytoplasmic HMGB1 translocation and release, butdid not increase
nuclear (or total cellular) HMGB1 levels [5]. In primary murine
peritoneal macrophages, however, LPS significantly elevated
HMGB1 levels in both cytoplasmic and nuclear fractions
(Fig. 5B). At the concentrations (100 mg/ml) that significantly
inhibited LPS-induced HMGB1 release, fetuin-A significantly
reduced both nuclear and cytoplasmic HMGB1 levels (Fig. 5B).
Discussion
In response to infection or injury, the liver re-prioritizes the synthesis
and systemic release of many APPs. One hepatic protein, fetuin-A, has
previously been suggested either as a negative or positive APP following
infection- or injury-elicited inflammation [29–31]. In the present study,
we found that circulating fetuin-A levels were time-dependently
decreased during endotoxemia and sepsis, supporting the notion that
fetuin-A functions as a negative APP during LSI.
During endotoxemia or sepsis, multiple early cytokines (such as
TNF-a and IFN-c) are responsible for counter-regulating hepatic
fetuin-A expression, thereby reducing circulating fetuin-A levels
(Fig. 6). Indeed, disruption of IFN-c expression impaired
endotoxin-induced suppression of hepatic fetuin-A expression in
vivo. It is thus plausible that IFN-c, a proinflammatory cytokine
predominantly derived from spleen [46], contributes to lethal
endotoxemia [47,48] or sepsis [49] partly by stimulating HMGB1
release [50] and partly by inhibiting hepatic fetuin-A expression.
A previously under-appreciated protective role for fetuin-A in LSI
has been suggested in the present study. First, the disruption of fetuin-A
expression rendered mice more susceptible to endotoxemia or sepsis.
Second, repetitive administration of fetuin-A conferred a dose-
dependent protection against these systemic inflammatory diseases.
In light of our observation that administration of fetuin-A markedly
reduced circulating levels of HMGB1, but not TNF-a (data not
shown), we propose that fetuin-A confers protection against lethal
endotoxemia and sepsis partly by inhibiting late mediators of these
diseases. Nevertheless, the current study can not exclude other
alternative mechanisms by which fetuin-A confers these protective
effects. For instance, fetuin-A may be capable of binding bacteria
[51,52],therebyaffecting macrophage-mediated pathogen elimination.
Furthermore, fetuin-A may facilitate macrophages-mediated ingestion
and elimination of apoptotic neutrophils [53,54], thereby preventing
secondary necrosis and passive leakage of injurious molecules (e.g.,
proteases, reactive oxygen species, and HMGB1) [55].
In vitro, highly purified intact fetuin-A effectively inhibited IFN-
c- and endotoxin-induced HMGB1 release in macrophage
cultures. These inhibitory effects were concentration-dependent,
and required the presence of sialic acid in the intact fetuin-A.
Although it is difficult to correlate the concentration-effect
relationship of fetuin-A in vitro and in vivo, a single injection of
fetuin-A at 100 mg/kg could theoretically produce a minimal
tissue level of 100 mg/ml fetuin-A (assuming even distribution in
all tissues including bone, muscle, blood, and others). It is thus
possible that the fetuin-A-mediated inhibition of IFN-c- or LPS-
induced HMGB1 release in vitro partly accounts for the observed
inhibition of serum HMGB1 levels in vivo. We propose that
endogenous fetuin-A functions as a negative regulator of HMGB1
release during lethal systemic inflammation. First, the time-
dependent decrease of circulating fetuin-A levels is accompanied
by parallel but contrary changes - a time-dependent increase - of
circulating HMGB1 levels in animal model of endotoxemia [5] or
sepsis [17]. Second, disruption of fetuin-A expression led to
significant elevation of serum HMGB1 levels during endotoxemia
and sepsis. Lastly, supplementation of fetuin-A resulted in
significant reduction of circulating HMGB1 levels during
endotoxemia and sepsis.
The mechanisms underlying fetuin-A-mediated suppression of
HMGB1 release may be complex. For instance, fetuin-A may
attenuate systemic HMGB1 accumulation indirectly by facilitating
macrophage-mediated phagocytotic elimination of apoptotic cells
[54]. This is relevant because prolonged accumulation of apoptotic
cells may allow these cells to enter secondary necrosis, leading to
rapid HMGB1 leakage. In addition, at the concentrations
(100 mg/ml) that significantly inhibited LPS-induced HMGB1
release, fetuin-A stimulated the formation of LC3-containing
punctuate structures (likely autophagosomes), and impaired LPS-
induced elevation of both cytoplasmic and nuclear HMGB1 levels.
At present, it is not yet known whether fetuin-A reduces
cytoplasmic HMGB1 levels by transcriptionally down-regulating
HMGB1 expression, or stimulating its degradation in an
autophagy-dependent fashion. Nevertheless, the fetuin-A-mediat-
ed reduction of cytoplasmic HMGB1 levels may underlie its
inhibition of endotoxin-induced HMGB1 release in macrophage
cultures.
In summary, we demonstrated that circulating fetuin-A levels
was time-dependently reduced during lethal endotoxemia and
sepsis, supporting the notion that fetuin-A functions as a negative
APP during LSI. The temporal decrease of circulating fetuin-A
levels ensures a rigorous innate immune response manifested by
excessive accumulation of early (e.g., IFN-c) and late (e.g.,
HMGB1) proinflammatory mediators. Supplementation with
exogenous fetuin-A could tilt the balance towards inhibiting active
HMGB1 release (Fig. 6). Thus, fetuin-A occupies an important
protective role against LSI by counter-regulating systemic
accumulation of late mediators (e.g., HMGB1).
Materials and Methods
Animal models of lethal endotoxemia and sepsis
This study was approved and performed in accordance with the
guidelines for the care and use of laboratory animals at the
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PLoS ONE | www.plosone.org 6 February 2011 | Volume 6 | Issue 2 | e16945Figure 5. Fetuin-A did not affect LPS-induced formation of LC3-containing cytoplasmic vesicles, but attenuated cytoplasmic
HMGB1 levels. A). Fetuin-A did not affect LPS-induced formation of autophagosomes, but reduced cytoplasmic HMGB1 staining. GFP-LC3 transfected
macrophages were stimulated with LPS (200 ng/ml) in the absence or presence of fetuin-A, and immunostained with HMGB1-specific antibodies.
Note that HMGB1 was predominantly localized in the nuclear region of un-stimulated macrophages (control) (left panels), but in both cytoplasmic
and nuclear regions of LPS-stimulated macrophages (middle panels). Fetuin-A reduced cytoplasmic HMGB1 staining in LPS-stimulated macrophages
(LPS + fetuin-A). Images are representative of three independent experiments with similar results. B). Fetuin-A reduced cytoplasmic and nuclear HMGB1
levels in LPS-stimulated macrophages. Thioglycollate-elicited peritoneal murine macrophages were stimulated with LPS in the absence or presence of
fetuin-A (100 mg/ml) for 16 h, and cytoplasmic nuclear fractions were isolated, and assayed for levels of HMGB1 with reference to a nuclear (PCNA) or
cytoplasmic (b-actin) markers. Blots are representative of two independent experiments with similar results. Bar graphs were mean 6 SD of two
independent experiments in duplicates (N=4).
#, P,0.05 vs negative control ‘‘- LPS’’; *, P,0.05 vs positive control ‘‘+ LPS’’.
doi:10.1371/journal.pone.0016945.g005
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genetic background-matched (male, 23–25 g) wild-type and fetuin-
A-deficient C57BL/6J mice were obtained from the Jackson
Laboratory (Bar Harbor, ME, USA) and Dr. Willi Jahnen-
Dechent’s laboratory, respectively. Wild-type Balb/C mice and
IFN-c-deficient Balb/C mice were also obtained from the Jackson
Laboratory.
Endotoxemia was induced by intraperitoneal injection of
endotoxin (lipopolysaccharide, LPS, E. coli 0111:B4, Sigma-
Aldrich, 10 mg/kg) as previously described [5]. As a clinically
relevant model, sepsis was induced by cecal ligation and puncture
(CLP) as previously described [20,22,56]. Purified fetuin-A
(Calbiochem, Cat. No. #341506) or asialofetuin-A (sialic acid
residues of fetuin-A removed by neuraminidase) were adminis-
tered intraperitoneally into mice, and animal survival rates were
monitored. In parallel experiments, mice were euthanized at
indicated time points to collect blood (by cardiac puncture) or liver
tissue, to measure HMGB1 or fetuin-A by Western blotting
analysis.
Cell culture
Murine macrophage-like RAW 264.7 cells and human
hepatocyte HepG2 cells were obtained from the American Type
Culture Collection (ATCC, Rockville, MD). GFP-LC3-transfected
RAW 264.7 cells were established as previously described [45].
Primary peritoneal macrophages were isolated from Balb/C mice
(male, 7–8 weeks, 20–25 grams) at 3 days after intraperitoneal
injection of 2 ml thioglycollate broth (4%) as previously described
[20,22,50,57]. Murine macrophages were pre-cultured in DMEM
medium (Gibco BRL, Grand Island, NY) supplemented with 10%
fetal bovine serum (FBS), 2 mmol/L glutamine, and 1% penicillin.
Adherent macrophages or HepG2 cells were gently washed with,
and cultured in, OPTI-MEM I medium 2 h before stimulation
with LPS, or IFN-c (Sigma-Aldrich, Cat. No. 14777, Louis, MO),
in the absence or presence of fetuin-A at indicated concentrations.
At indicated time points after stimulation, intracellular or
extracellular levels of HMGB1, TNF-a, or fetuin-A, were
determined by Western blotting analysis or ELISA as previously
described [20,50].
Purification of intact fetuin-A
Gel filtration chromatography was performed using a HiPrep
TM
26/60 Sephacryl S-100 high resolution column. Sample was
eluted by 1x PBS at a flow rate of 1.0 ml/min, and gel filtration
fractions were subjected to protein analysis by SDS-PAGE gel
electrophoresis. The filtration fraction enriched in fetuin-A protein
was further purified by ion-exchange chromatography. Briefly, gel
filtration fraction was loaded onto a 5-ml HiTrap
TM SP HP
column pre-equilibrated in buffer A (50 mM NaAc, pH 7.5), and
the column was washed with 5% Buffer B (1.0 M NaCl in 50 mM
NaAc) until the A280 dropped below 1% of its maximum. Proteins
bound to the column were eluted by a linear gradient of 0–20%
Buffer B over 40 min at a flow rate of 2.5 ml/min, and ion-
exchange fractions were subjected to purity analysis by SDS-
PAGE gel electrophoresis.
Western blotting analysis
Following SDS-PAGE electrophoresis, proteins were hybridized
with specific primary antibodies. Rat HMGB1-specific and bovine
fetuin-A-specific polyclonal antibodies were generated in rabbits as
previously described [5,43]. Human fetuin-A-specific polyclonal
antibodies were obtained from Santa Cruz (Cat. No. sc-9663).
Monoclonal antibodies against b-actin were obtained from Abcam
(Cat. No. mAbcam 8226). After incubation with the alkaline
phosphotase-conjugated secondary antibodies, the signal was
detected with the colormetric alkaline phosphatase assay kit (Bio-
Rad Laboratories). The relative band intensity was quantified by
using the NIH Image 1.59 software to determine fetuin-A levels
with reference to b-actin, or HMGB1 levels with reference to
standard curves generated with purified HMGB1 as previously
described [22,43].
TNF-a ELISA
TNF-a levels were determined using ELISA kits (Catalog no.
MTA00, R & D Systems, Minneapolis, MN) with reference to
standard curves of purified recombinant TNF-a at various
dilutions as previously described [20,22].
Visualization of LC3-containing cytoplasmic vesicles
(autophagosomes). Autophagy, literally meaning ‘‘self-
eating’’, refers to an evolutionarily conserved process for
degrading organelles and cytoplasmic macromolecules. It begins
with the formation of double-membraned structures called
phagophores, which elongate and engulf portions of cytoplasm
to form autophagosomes. The basic principle of autophagy assays
is to measure the transfer of a soluble, membrane-impermeant
LC3 protein from cytosol to autophagic vesicles (autophagosomes).
Murine macrophage-like RAW 264.7 cells stably transfected with
GFP-LC3 were stimulated with LPS in the absence or presence of
Figure 6. Hypothetical role of fetuin-A in lethal systemic
inflammation. Fetuin-A is predominantly synthesized in, and consti-
tutively secreted by the liver to maintain abundant basal circulating
levels (e.g., 1100–1350 mg/ml in mice). In response to lethal endotox-
emia (LPS) or sepsis (CLP), innate immune cells (such as macrophages)
sequentially release early (e.g., TNF-a and IFN-c) and late (e.g., HMGB1)
proinflammatory mediators. These early proinflammatory cytokines
(e.g., TNF-a, IFN-c and perhaps others) participate in the down-
regulation of hepatic fetuin-A expression, allowing propagation of a
rigorous inflammatory response manifested by excess accumulation of
late proinflammatory mediators (such as HMGB1). On the other hand,
fetuin-A functions as a negative regulator of the innate immune
response by inhibiting LPS- or IFN-c-induced HMGB1 release in
macrophages.
doi:10.1371/journal.pone.0016945.g006
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LC3-II punctate structures under fluorescence microscope as
previously described [45].
Fluorescence Immunostaining
Macrophage cultures were fixed with 2% formalin (10 min),
and permeabilized with 0.1% Triton X-100 (in PBS, 1 min, room
temperature). After extensive washing with 1x PBS, cells were
incubated sequentially with antigen-affinity-purified rabbit anti-
HMGB1 antibodies or anti-fetuin-A polyclonal Abs, donkey anti-
rabbit secondary antibodies conjugated with red Alexa fluor 594
(Invitrogen, Cat # 404239, Eugene, OR), and Vectashield
mounting medium with DAPI (Vector, Cat #1200, Burlingame,
CA). Images were captured using a fluorescence microscope (Carl
Zeiss Microimaging) as previously described [43]. Alternatively,
localization of HMGB1 was examined by a cell fractionation/
Western blotting technique as previously described [20]. After
fractionation, the protein content of different fractions was
determined by a Bradford method, and each fraction was assayed
for levels of various protein by Western blotting analysis using
primary antibodies specific for HMGB1, a cytoplasmic protein (b-
actin, Santa Cruz Biotechnology), and a nuclear protein (PCNA,
BD Biosciences).
Statistical Analysis
Data are expressed as mean 6 SD of at least 2–3 independent
experiments (n=2–3). One-way ANOVA was used for compar-
ison among all different groups. When the ANOVA was
significant, post-hoc testing of differences between groups was
performed using Tukey’s test. A P value ,0.05 was considered
statistically significant. The Kaplan-Meier method was used to
compare the differences in mortality rates between groups. A P
value ,0.05 was considered statistically significant.
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